EUCTR2013-004025-88-ROActive, not recruitingPhase 1
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia AAn open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of N8-GP in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A - pathfinder™6
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- ovo Nordisk A/S
- Enrollment
- 125
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Male
Inclusion Criteria
- •- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
- •- Male, age < 6 years at the time of signing informed consent
- •- Diagnosis of severe haemophilia A (factor VIII activity level < 1%) based on medical records or central laboratory results
- •- No prior use of purified clotting factor products (5 previous exposure to blood components is acceptable)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 125
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- Any history of FVIII inhibitor (defined by medical records)
- •- Known or suspected hypersensitivity to trial product or related products
- •- Previous participation in this trial. Participation is defined as administration of trial product
- •- Receipt of any investigational medicinal product within 30 days before screening
- •- Congenital or acquired coagulation disorder other than haemophilia A. Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise patient’s safety or compliance with the protocol.
- •- Patient’s parent(s)/legally acceptable representative(s) mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation
Investigators
Similar Trials
Active, not recruiting
Phase 1
A research study looking at how a factor VIII medicine called turoctocog alfa pegol (N8-GP) works in people with haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2017-003788-36-HUovo Nordisk A/S170
Active, not recruiting
Phase 1
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2013-004025-88-GRovo Nordisk A/S125
Active, not recruiting
Phase 1
A research study looking at how a factor VIII medicine called turoctocog alfa pegol (N8-GP) works in people with haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2017-003788-36-DEovo Nordisk A/S170
Active, not recruiting
Phase 1
A research study looking at how a factor VIII medicine called turoctocog alfa pegol (N8-GP) works in people with haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2017-003788-36-HRovo Nordisk A/S170
Active, not recruiting
Phase 1
A research study looking at how a factor VIII medicine called turoctocog alfa pegol (N8-GP) works in people with haemophilia AEUCTR2017-003788-36-GBovo Nordisk A/S170